Common Side Effects of Tremfya
Tremfya (guselkumab), an IL-23 inhibitor for plaque psoriasis, psoriatic arthritis, and Crohn's disease, most often causes upper respiratory infections like colds or sinus issues, affecting about 15% of users in trials. Other frequent reactions include headache (around 5%), joint pain, diarrhea, fatigue, and injection-site reactions such as redness, itching, or pain.[1][2]
Serious Side Effects and Risks
Rare but severe risks include infections (e.g., tuberculosis reactivation or fungal infections), with warnings to screen patients beforehand. Hypersensitivity reactions like swelling or breathing difficulty occur in under 1%. Increased malignancy risk is monitored, though not proven causal. For Crohn's patients, monitor for bowel perforation or abscesses. Liver enzyme elevations appear in some IBD cases.[1][3]
Side Effects in Specific Conditions
In psoriasis trials, infections topped lists at 14-19%; psoriatic arthritis added fatigue and nausea. Crohn's studies showed similar infection rates (14%) plus worsening GI symptoms in 1-2%. Long-term data (up to 5 years) confirm no new major signals beyond infections.[2][4]
How Long Do Side Effects Last?
Most resolve within days to weeks; injection reactions fade in 1-3 days. Persistent infections or hypersensitivity need medical attention. No chronic effects dominate post-treatment.[1]
Who Gets Side Effects Most?
Higher rates in Crohn's patients (infections up to 20%) versus psoriasis (under 15%). Elderly or immunocompromised face elevated infection risk; avoid live vaccines during treatment.[3]
Managing and Reporting Side Effects
Use sterile technique for self-injections to cut site reactions. Report serious issues to FDA MedWatch or doctor. Prescribing info urges stopping if active infection arises.[1][2]
Sources:
[1] Tremfya Prescribing Information (Janssen)
[2] FDA Label for Guselkumab
[3] Drugs.com Tremfya Side Effects
[4] ClinicalTrials.gov Guselkumab Studies